AKAlba J. Kihn-Alarcón

Alba J. Kihn-Alarcón

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alba J. Kihn-Alarcón has a total of 204 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey

    by Yuksel Urun, Kannan Sridharan, Anca Zgura, Anas Zayed, Martin Ignacio Zapata Laguado, Tarkan Yetisyigit, Akihiro Yano, Mike Wenzel, Nuno Vau, Deniz Tural, et al.

    Background: Renal Cell Carcinoma (RCC) represents a growing global health burden, with rising incidence and mortality worldwide. Despite major therapeutic advances, access to novel systemic treatments remains uneven across countries and regions. Methods: We conducted a cross-sectional, web-based international survey to assess the availability and reimbursement status of 20 innovative systemic therapies for RCC. Responses were collected from 144 clinicians, including medical oncologists, radiation oncologists, urologists, and nuclear medicine specialists, across 58 countries. Analyses examined associations between national income level, gross domestic product (GDP), and treatment availability. Findings: Thirty-six percent of the countries analyzed had at least 15 of the 20 therapies available. Full reimbursement for at least 15 of the selected innovative therapies was reported in six countries (10%), while 21 countries (36%) fully reimbursed 10-14 therapies and 13 countries (23%) reimbursed 1-9 therapies. In contrast, no full reimbursement for any of the assessed therapies was reported in 18 countries (31%). Higher national income level was significantly associated with greater availability of innovative therapies (Kruskal–Wallis test, P < .0001). Armenia (0.709), Greece (0.685), and Israel (0.666) exhibited the highest GDP-adjusted Drug Availability Index (DAI), whereas India (5.195), Nigeria (4.612), and Morocco (3.794) demonstrated the greatest number of available therapies per US$1000 of GDP per capita. Interpretation: Access to innovative systemic therapies for RCC remains highly unequal at the global level, with reimbursement posing a major barrier even where drugs are available. Internationally coordinated efforts addressing health policy, infrastructure, and equitable pricing are urgently required to ensure that advances in RCC treatment translate into improved outcomes for patients across diverse economic settings.

  • Open Access

    JCO Global Oncology Latin America Series

    by Maria T. Bourlon, Alba Kihn-Alarcón, Paola I. Valdez-Sandoval

  • Open Access

    TOM: Treatment Outcome Monitor - A Web-Based Tool Designed Specifically for Clinics With Limited Resources

    by Saurabh Shashikumar Nair, Alba Kihn Alarcon, Maritza Elodia Cupil Barrios, Milton Estuardo Ixquiac Cabrera, Mynor Villeda, Joseph Steyn, Anneray Richards, Ricardo Ruggeri, Loida Orozco, Angel Velarde, et al.

    Background: Although three-fourths of cancer deaths are expected to occur in low- and middle-income countries (LMICs) by 2030, most cancer research still comes from high-income countries. One barrier to cancer research in LMICs is lack of infrastructure for systematic data collection, including electronic medical record systems. We developed Treatment Outcome Monitor (TOM), a cloud-based tool for tracking cancer patient outcomes, designed specifically for resource-limited settings. Methods: TOM was developed through iterative design cycles with continuous feedback from health care providers from across the world. We focused on creating a simple, web-based solution that addresses real-world challenges in resource-limited settings. The platform includes questionnaire creation, patient data tracking, and automated patient communication via text or email. We created detailed user instructions for 9 core tasks and conducted usability testing. Six health care professionals (4 radiation oncologists, 1 oncology surgeon, and 1 medical physicist) completed all tasks and rated their confidence and ease of use on a 5-point Likert scale (1 = lowest, 5 = highest). Results: During development, end users identified critical requirements that shaped the platform. Key features included cloud-based architecture to eliminate local IT infrastructure needs, printable questionnaires for offline use during internet outages, patient messaging to address poor clinic follow-up rates, and integration of standardized patient-reported outcome measures. The platform achieved high usability scores. Five users (83%) rated all tasks as 4 or 5 for both confidence and ease of use. One user gave lower ratings for some tasks (ratings of 3). Overall, 92% of all responses (99 of 108 total ratings across all users and tasks) scored 4 or 5, indicating high usability. Conclusions: We successfully developed a user-friendly, cloud-based platform for cancer outcome monitoring and data collection in resource-limited settings. Through collaborative design with end users, TOM addresses practical barriers including limited IT infrastructure, unreliable internet, and poor patient follow-up. The high usability scores demonstrate that thoughtful, user-centered design can create tools that are both technically sound and appropriate for resource-limited contexts. By simplifying systematic data collection, TOM may help enable clinics in LMICs to participate more fully in cancer research.

  • Guideline Utilization in Oncology: Addressing Barriers and Facilitators in Latin America and the Caribbean

    by Yanin Chavarri-Guerra, Luis Corrales, James D. Morgante, Henry Gomez, Alba Kihn-Alarcón, Rodrigo Munhoz, Els Dams

    PURPOSE: This study aimed to explore the usage patterns, barriers, and facilitators of cancer treatment guidelines among oncologists in Latin America and the Caribbean. METHODS: A cross-sectional survey was conducted in March 2023 among physicians in Latin America and the Caribbean who care for patients with cancer. Respondents were recruited via the ASCO member database. Data were collected using a self-reported questionnaire that assessed demographics, guideline usage, and barriers to implementation. Descriptive statistics were used to analyze the data. RESULTS: Of the 1,265 invited physicians, 140 responded (11% response rate). Most respondents reported frequent use of guidelines, with 47.9% using them often and 40.7% always. The guidelines that were used the most were from the National Comprehensive Cancer Network (88.5%), European Society for Medical Oncology (76.3%), and ASCO (70.5%). The top barriers to guideline use included lack of diagnostic tools and access to medications (47.7%), and institutional restrictions (19.7%). Facilitators included access to necessary resources (79.8%) and country-specific guidelines (61.2%). CONCLUSION: Although oncologists in Latin America and the Caribbean frequently rely on international guidelines, significant barriers, particularly resource limitations, impede full implementation. Addressing these barriers through improved infrastructure and adapted guidelines is essential for enhancing cancer care in the region.


  • Open Access

    HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America

    by Carolina Bernabe-Ramirez, Ana I. Velazquez, Coral Olazagasti, Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Jose Corona Cruz, Ivy Riano, Christina Adaniel, Francisca Ramirez, Jesus Anampa, et al.

    PURPOSE: The HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer.METHODS: This international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice.RESULTS: A total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care.CONCLUSION: The COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.


  • Open Access

    Years of Potential Life Lost Because of Breast and Cervical Cancers in Guatemala

    by Alba J. Kihn-Alarcón, Juan F. Alvarado-Muñoz, Loida I. Orozco-Fuentes, Erwin Calgua-Guerra, Vicky Fuentes-De Falla, Angel Velarde

    Worldwide cervical and breast cancers are among the most commonly diagnosed cancers and are leading cause of cancer deaths among females in low- and middle-income countries. In Guatemala, breast and cervical cancers are the main cause of cancer-related deaths among women. Therefore, the aim of this study was to determine the years of potential life lost (YPLL) as an indicator of premature deaths as a result of breast and cervical cancers. Data on the number of deaths as a result of breast and cervical cancers (International Classification of Diseases [10th revision] codes C50 and C53) between 2012 and 2016 and age composition by quinquennials were retrieved from the Health Information System of the Guatemalan Health Ministry. On the basis of each individual’s age at death, YPLL was estimated for females between 20 and 70 years of age. A total of 1,476 deaths related to breast and cervical cancers was reported over the study period. The trend in breast cancer mortality rate and YPLL did not change from 2012 to 2016. The cervical cancer mortality rate has decreased to 10 deaths per 1 million habitants (P = .046). There has been a reduction in YPLL because of cervical cancer, from 50.18 YPLL in 2012 to 29.19 YPLL by 2016, mainly in women between 30 and 34 years of age, in whom YPLL decreased from 600 to 112.50 (P = .046). Cervical cancer screening has significantly reduced the mortality rate of this malignancy, and screening of breast cancer must include creating awareness of the disease and providing access to women at risk.


  • Open Access

    Liver Cancer in Guatemala: An Analysis of Mortality and Incidence Trends From 2012 to 2016

    by Alba J. Kihn-Alarcón, María F. Toledo-Ponce, Angel Velarde, Ximing Xu

    PURPOSE Guatemala has the highest mortality and incidence of liver cancer in Central and South America. The aim of this study is to describe the extent of liver cancer in the country from 2012 to 2016 and the associated risk factors. METHODS A secondary analysis was performed using liver cancer mortality and morbidity data and data on risk factors, such as hepatitis B virus infection, cirrhosis, and alcoholism. RESULTS Analysis revealed that liver cancer causes approximately 20% of cancer deaths in the country, is more frequent in the population older than age 65 years old, and is increasing in those age 30 to 44 years. More than 25% of deaths occurred in the North and West regions. The incidence of major risk factors for development of liver cancer has decreased. CONCLUSION The high mortality of liver cancer compared with its incidence indicates that most patients are diagnosed at late stages. To reduce the burden of liver cancer, creation of strategies for earlier detection is needed. (C) 2019 by American Society of Clinical Oncology